Pharmafile.com’s weekly COVID-19 news round-up
The past week has seen lots of COVID-19 developments; Avacta’s 20-minute COVID test has gained clinical validation, the EMA has begun a review of GSK and Vir’s treatment, and a new study of the Pfizer-BioNTech shot has suggested it has a significantly reduced efficacy against the South African variant of the virus.
1. Adagio raises $336 million to advance COVID-19 antibody – Published 20/04/2021
Adagio Therapeutics has financed $336 million to support the rapid advancement of their novel ADG20 antibody for the treatment and prevention of COVID-19.
2. Avacta’s COVID-19 lateral flow test gains clinical validation – Published 20/04/21
Avacta have announced positive data from the clinical validation of its AffiDX SARS-CoV-2 antigen lateral flow test, based on a clinical study conducted in Europe on 98 positive COVID-19 samples.
3. Pfizer vaccine: Study finds increased breakthrough rates of South African variant – Published 19/04/21
A study published by Tel Aviv University has found an increased breakthrough rate of the South African variant of COVID-19 in people who have been vaccinated with the Pfizer vaccine, finding the jab to have a significantly reduced efficacy rate against the mutation.
4. Merck cease development of $425 million COVID-19 treatment – Published – 16/04/21
Merck (MSD) have ended the development of their MK-7110 drug for the treatment of hospitalised patients with COVID-19.
5. EMA to begin review of GSK and Vir’s COVID-19 treatment – Published 16/04/21
The EMA have begun a review of GSK and Vir Biotechnology’s investigational COVID-19 antibody (VIR-7831) for patients at high risk of progressing to a severe form of the virus.
ACM Biolabs has announced positive topline results from its phase 1 trial of ACM-001, an …
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …